Circelli Luisa, Tornesello Marialina, Buonaguro Franco M, Buonaguro Luigi
a Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori , "Fondazione Pascale" - IRCCS , Naples , Italy.
Hum Vaccin Immunother. 2017 Aug 3;13(8):1774-1777. doi: 10.1080/21645515.2017.1321725. Epub 2017 Jun 12.
Cancer vaccines are designed to stimulate the body's immune system to kill tumor cells. To improve their immunogenicity, vaccine antigens must be combined with adjuvants which are able to stimulate the innate immunity and potentiate the adaptive immune response. In the last years a new generation of adjuvants mimicking the natural microbial ligands have been developed. In particular, several TLR ligands have been extensively explored as vaccine adjuvants and many preclinical and clinical studies have been conducted. However, the road to approval of such adjuvants for clinical use is still to go.
癌症疫苗旨在刺激人体免疫系统杀死肿瘤细胞。为提高其免疫原性，疫苗抗原必须与能够刺激先天免疫并增强适应性免疫反应的佐剂相结合。近年来，已开发出新一代模拟天然微生物配体的佐剂。特别是，几种Toll样受体（TLR）配体已被广泛探索用作疫苗佐剂，并已开展了许多临床前和临床研究。然而，此类佐剂获批用于临床的道路仍任重道远。
